FDA Approves MATZIM LA — Actavis Pharma, Inc.

# FDA Approves Actavis Pharma's Generic Diltiazem Extended-Release Formulation Actavis Pharma, Inc. received FDA approval for MATZIM LA (diltiazem hydrochloride), an extended-release oral formulation that expands the company's cardiovascular portfolio and positions it to capture market share in the competitive calcium channel blocker segment. The approval of the generic alternative is expected to increase treatment accessibility and drive price competition in the diltiazem market.